Braveheart Bio
BRVE
20.39
+1.12
+5.81%
Braveheart Bio
US · BRVE
#2845 by market cap
Listed 2026
20.39
+1.12
+5.81%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 29 in the most recent period (2026/Q3).
- Total institutional ownership rose 86.1 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 86.07% +86.07pp
- Institutions
- 29 +29
- As of
- 2026/Q3 vs. prior period
Holder types
VC/PE Fund60.44%
Mutual Fund16.46%
Individual/Insider14.87%
Public Company9.10%
Other12.85%
Top holders as of 2026-08-07
Forbion Capital Partners B.V.
26.74% · 21.83M sh
OrbiMed Advisors LLC
14.91% · 12.18M sh
Andreessen Horowitz LLC
12.53% · 10.23M sh
Travis Murdoch
10.21% · 8.33M sh
FMR
9.29% · 7.59M sh
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
9.09% · 7.42M sh
Frazier Life Sciences Management, LP
6.26% · 5.11M sh
Capital Research
2.86% · 2.33M sh
David Malek
1.24% · 1.01M sh
Vanguard Capital Management, LLC
1.39% · 1.13M sh
James Rickey
0.86% · 703.58K sh
Jason Coloma
1.33% · 1.10M sh
Christopher Viehbacher
0.75% · 609.52K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
34 filings tracked · 22 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Forbion Capital Partners B.V. | -- | 26.74% |
| OrbiMed Advisors LLC | -- | 14.91% |
| Andreessen Horowitz LLC | -- | 12.53% |
| Travis Murdoch | Chief Executive Officer | 10.21% |
| Jason Coloma | Former Director | 1.33% |
| David Malek | Director | 1.24% |
| James Rickey | Chief Financial Officer | 0.86% |
| Christopher Viehbacher | Independent Chairperson | 0.75% |
| Michele Anderson | Chief Development Officer | 0.41% |
| David Lubner | Independent Director | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-06 | OrbiMed Advisors LLC | -- | Private Acquisition | +1,940,000 | $18.00 |
| 2026-08-06 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +9,132,420 | -- |
| 2026-08-06 | David Lubner | Independent Director | Private Acquisition | +55,555 | $18.00 |
| 2026-08-06 | Christopher Viehbacher | Independent Chairperson | Private Acquisition | +83,333 | $18.00 |
| 2026-08-06 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Derivative Exercise and Retained | +7,420,091 | -- |
| 2026-08-06 | Forbion Capital Partners B.V. | -- | Private Acquisition | +3,600,000 | $18.00 |
| 2026-08-06 | Forbion Capital Partners B.V. | -- | Derivative Exercise and Retained | +17,123,287 | -- |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Private Acquisition | +1,100,000 | $18.00 |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Derivative Exercise and Retained | +9,132,420 | -- |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-06 | David Malek | Director | Private Acquisition | +4,166 | $18.00 |
| 2026-08-06 | James Rickey | Chief Financial Officer | Private Acquisition | +27,777 | $18.00 |
| 2026-08-06 | Michele Anderson | Chief Development Officer | Private Acquisition | +1,111 | $18.00 |
| 2026-08-06 | Travis Murdoch | Chief Executive Officer | Private Acquisition | +83,333 | $18.00 |
| 2026-08-04 | OrbiMed Advisors LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | David Lubner | Independent Director | Other Derivative Acquisition | +60,000 | $18.00 |
| 2026-08-04 | Christopher Viehbacher | Independent Chairperson | Other Derivative Acquisition | +30,000 | $18.00 |
| 2026-08-04 | Christopher Viehbacher | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | Erez Chimovits | Independent Director | Other Derivative Acquisition | +30,000 | $18.00 |
| 2026-08-04 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Braveheart Bio discussion 0 comments